Healthtronics — Investor Presentation (December 2004)
63 slides from Healthtronics's investor presentation, Dec 14, 2004
Slide 1: Presentation of the New HealthTronics
Exhibit 99.1 Presentation of the New HealthTronics December 14, 2004 Brad A. Hummel President & CEO
Slide 2: Forward-looking statements
Statements in this presentation that are not strictly historical, including statements regarding plans, objective and future financial performance, are “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Although
Slide 3: Agenda
Agenda Introduction of Management Team Merger Highlights 2005 Highlights Operating Groups 2005 Financial Forecast Summary Q&A The New HealthTronics
Slide 4: Management Team
Management Team Brad A. Hummel – CEO & President John Q. Barnidge – CFO & Senior VP Joseph M. Jenkins, M.D. – President, Urology Klaas F. Vlietstra – Interim President, AKSV A. Michael Stolarski – President, Orthopaedics Robert W. Bachman – Sr. VP, AKSV Christopher B. Schneider – Sr. VP, Device Sale
Slide 5: Merger Highlights
Merger Highlights Creates Broad Based Urology Platform Provides for More Focused Enterprise Strengthens Balance Sheet Yields Substantial Synergy
Slide 6: 2005 Highlights
2005 Highlights Urology Group: Revenues Increase 10% Operating Income Increases 10% Solid Traction in Prostate Therapies Medical Device: Revenues Grow 20% to $27mm Litho Production Rationalized Introducing New Cysto Table Orthotripsy Revenues Increase 20% Contributing Earnings Improving Payors Outlo
Slide 7: 2005 Highlights: Consolidated Operations Summary
2005 Highlights: Consolidated Operations Summary of Income Statement (1) ($ in millions) 2005 Forecast Revenues $300 (1) Adjusted EBITDA $50 (1) Net Income $17 (1) EPS $0.48—$0.53 (1) Represents Midpoint of Estimates Range
Slide 8: Urology Services
UROLOGY SERVICES Joseph M. Jenkins, M.D. President, Urology W. Price Dunaway Senior VP, Urology
Slide 9: Leading Competitive Position
Leading Competitive Position Partnering with 1/3 of Nation’s Urologists Veteran Management Team Bringing Cutting-edge Therapies to Market Successful Partnership Model Proven Execution
Slide 10: Core Objectives
Core Objectives Leverage Urology Channel Trusted Advisor to our Partners Value-added Products and Services Facilitate Marketplace Consolidation Growing Revenue & Taking Share Expanding Platform Expand Margins HOPPS Rate Increase: Pricing Stability Wholesale Pricing Power Operating Efficiencies
Slide 11: Market Scope
Market Scope Drivers: Aging “Boomers” Fast Growing Segment – 50+ Year Old Male First Baby Boomer not yet 60 Years Old Increasingly Informed Patient New Technologies Delivery System Shift – “Following the Patient”
Slide 12: Lithotripsy
Lithotripsy Cost Effective, Non-invasive, Efficacious Fractional Cost of Surgical Alternatives Market Scope 250,000 Cases per Year $2,000 per Case Revenue $500M Revenue Market Physician-driven Therapy No Alternative Therapy
Slide 13: Lithotripsy Partnership Economics
Lithotripsy PARTNERSHIP ECONOMICS Doctors (LPs) HealthTronics (GP) Sale of Equipment Equipment & Consumables $ $ Reimbursement for Procedure Maintenance Lithotripsy Partnership Management 65% 35% Partnership Distributions Long Term Partnerships Non-Competes
Slide 14: Prostate Therapy – BPH
Prostate Therapy – BPH Benign Prostatic Hyperplasia Non-cancerous Enlargement of the Prostate Market Scope Affects 50% of Men Over Age 60 13 Million American Men in 2004 Growth Rate From 40,000 to 360,000 Minimally Invasive Treatments $650 Million—$700 Million Market Multiple Treatment Methodologies
Slide 15: Prostate Therapy – BPH: TUMT and GreenLight
Prostate Therapy – BPH TUMT Microwave of the Prostate In-office Procedure Wholesale Provider $3,600 Medicare / $1,700 Wholesale GreenLight Laser Photoselective Vaporization of the Prostate (PVP) Hospital Outpatient Procedure Partnership Delivered $3,700 Medicare / $1,900 Wholesale
Slide 16: Prostate Therapy – Prostate Cancer
Prostate Therapy – Prostate Cancer Market Scope Second Most Common Cancer in American Males 230,000 New Cases per Year in the U.S. Baby Boomer Impact $5B market Dramatic Increase in Public Awareness Participating in the Diagnosis PSA Testing Anatomical Path
Slide 17: Prostate Cancer Treatment Alternatives
Prostate Therapy – Prostate Cancer Treatment Alternatives Total Ablation Radical Surgery Radiation Cryotherapy HIFU Focal Ablation Cryotherapy HIFU The New HealthTronics
Slide 18: Prostate Cancer: Cryotherapy and HIFU
Prostate Therapy – Prostate Cancer Cryotherapy Partnership Model Specialized MD Hospital Environment $4,500 per Case HIFU Project FDA Clinical Trials Underway High Efficacy / Patient Satisfaction
Slide 19: Other Developments
Other Developments Delivering into our Network Treating Andropause Testosterone Testing Qualigen Marketing Agreement Scientifically Validated Nutritional Supplements Formulated by Urologists Anatomical Pathology
Slide 20: Uropathology
Uropathology Market Market is Approximately $500 Million 7,500 Private Practice Urologists Approximately 10 Prostate Biopsies / Month Each Patient = Approximately $600 Revenue 60% of Patients are Medicare Medicare Reimbursement is Excellent
Slide 21: Overview of Prostate Biopsy Process
Overview of Prostate Biopsy Process Patient Presents w/ Elevated PSA Qwest Physician Needle Biopsies Prostate Lab Corp Physician Staff Determines Where to Send Biopsy Local Pathologist Others Courier Transports Biopsies to Lab HTRN Lab Processes Biopsies Physician Receives Results and Determines App
Slide 22: Uropath Advantage
HealthTronics Uropath Advantage – Big Lab Technology, Small Lab Service Timeliness & Accuracy – Turnaround Within 48 Hours Technology – Electronic Reporting Customer Service – Physician Oriented Pathologists
Slide 23: Development Strategy
Development Strategy Beta Users HTRN Physician Partners Beta Sites Georgia, Louisiana & Mississippi Investment 2005 CapEx $2 Million
Slide 24: Device Sales & Service
DEVICE SALES & SERVICE Christopher B. Schneider Senior VP, Device Sales & Service
Slide 25: Strategic Imperatives
Strategic Imperatives Launch Urology Imaging Table 2Q 2005 Drive Growth via Comprehensive Distribution Channel Establish Sales & Marketing Culture Capitalize on Manufacturing & Engineering Platform
Slide 26: Devices: Lithotripters
Devices: Lithotripters Market Scope: Total US Installed Base of 650 Units Average Selling Price of $390,000 35% of US Market is Spark Gap Technology US HTRN Manufactured Installed Base of 220 Units Opportunities: Dual Branding Strategy to Expand Spark Gap Market New Model with Multi-Functional Capab
Slide 27: Devices: Urology Imaging System
Devices (cont.): Urology Imaging System Market Scope: Total US Installed Base of 4,500 Units 200 - 250 Units Purchased in US Annually at $300,000 ASP Urologist Influential in Equipment Decision Market Moving Toward Multi-Specialty Surgical Units Opportunities: Finalizing Leapfrog Design with 2Q 2005
Slide 28: HTRN New Urology Imaging System
HTRN New Urology Imaging System Multifunctional Surgical Procedures Traditional Urology Procedures
Slide 29: Devices: Other Products
Devices (cont.): Other Products Patient Management Tables: US Installed Base of 4000 Units, HTRN 450 Units Installed Comprehensive Dealer Network, OEM Supplier PSA Testing: 6 Million PSA Tests Performed Annually, $200 Million Market In-Office Testing Approved and now Reimbursed by All Payors Signed
Slide 30: Service
Service Engineering: Installed Base/Network: Currently Service 38% of US Lithotripter Installed Base 180 of 250 Total HTRN Service Base is Within Partnerships 36 Field Engineers Trained in Lithotripsy and X-Ray 530 Units Generating Consumable Revenue Opportunities: ISO Certification in Atlanta Manuf
Slide 31: Summary
Summary: Promote Products & Services via Network of 3,000 MDs: 12 Business Development Personnel 250 Clinical Technologists 36 Field Service Engineers Grow Presence In Urology and Patient Management Market: 7 Direct Sales Personnel, 15 Dealer Organizations Marketing and Distribution Agreements Innov
Slide 32: Orthopaedic Lithotripsy
ORTHOPAEDIC LITHOTRIPSY A. Michael Stolarski President, Orthopaedics
Slide 33: Overview
Overview Shock Wave Surgery for Musculoskeletal Injuries Applications: Plantar Fasciitis (Heel Spur) Lateral Epicondilitis (Tennis Elbow) Other Leading Edge Position Patented Technology: OssaTron™ FDA Approvals OssaTron®
Slide 34: Plantar Fasciitis
Plantar Fasciitis Market Opportunity Drivers: 250,000 New Chronic Cases Per Year Accelerating Payor Acceptance Insurance Covered Population: Approx. 36 Million Reimbursement: $2,000—$2,500 per Case
Slide 35: Market Opportunity
Market Opportunity Estimated # of Estimated Condition Cases per Year Market Size *Heel Spurs 250,000 $500 million *Tennis Elbow 250,000 $500 million Non-Union Fractures 75,000 $300 million Achilles Tendonitis 100,000 $250 million Patellar Tendonitis 100,000 $250 million Shoulder Tendonitis 100,000 $
Slide 36: Economic Thesis
Economic Thesis Large Untapped Market Current Surgery (Plantar Fasciotomy) Less Efficacious than ESWS Crutches Open Wound Recurring Revenue Partnership Model
Slide 37: Delivery
Delivery Active with 49 Partnerships in 47 States Over 4,200 Trained Physicians Average Location Treating 150 Cases per Year Average Partnership Stake: 50-60% Outcomes Appear to be Better than Surgery HealthTronics Re-treat Rate of <10%
Slide 38: Challenges
Challenges Payor Acceptance Floodgate Resistance Building a Patient Constituency Device Differentiation High Energy vs. Low Energy
Slide 39: Orthopaedic Lithotripsy: Growth
Orthopaedic Lithotripsy: Growth Increase Number of Contracted Payors Increase Worker’s Compensation Cases Leads to Greater Utilization in Field
Slide 40: Specialty Vehicle Manufacturing
SPECIALTY VEHICLE MANUFACTURING Robert W. Bachman Senior VP, AKSV Klaas F. Vlietstra Interim President, AKSV
Slide 41: Specialty Vehicle Manufacturing
SPECIALTY VEHICLE MANUFACTURING AK Specialty Vehicles is Global Leader in the Design, Engineering and Construction of Specialty Vehicles. Medical Imaging Broadcast & Communications Command/Homeland Security
Slide 42: Medical Imaging
Medical Imaging MRI PET/CT PET CT Cardiac Lithotripsy
Slide 43: Leadership: Position in Mobile Medical Worldwide
Leadership Position in Mobile Medical Worldwide Manufacturing Facilities in U.S. and Europe Strategic Relationships for all Modalities GE Healthcare Technologies Philips Medical Systems Siemens Medical Solutions Extraordinary Market Breadth Australia • Finland Korea • Norway Italy • United Kingdom G
Slide 44: Leadership: Strong Customer Base
Leadership Position in Mobile Medical Worldwide Strong Customer Base Alliance Imaging DMSI Insight Health Services Corp. Alliance Medical Ltd. (UK) 94 Unique Customers in 2003-2004 Significant Barriers to Entry OEM Certification Technology and Experience
Slide 45: Leadership: Market Opportunities
Leadership Position in Mobile Medical Worldwide Market Opportunities Expand Global Presence Pan Asia Australia Canada Educate Market to Stimulate Organic Growth OEM Sponsored Product Macro-Economics Encourages Shared Services Technology Initiatives Develop 3T Delivery Platform MRI/Ultrasound Product
Slide 46: Broadcast & Communications
Broadcast & Communications ENG DSNG SNV EFP
Slide 47: Broadcast & Communications
Broadcast & Communications
Slide 48: Market Leader in Broadcast & Communications
Market Leader in Broadcast & Communications Unique Competency Systems Design/Integration Consult Design Procure Integrate Train Leverage Broadcast Systems Capabilities to Command/Homeland Security Market
Slide 49: Leadership: Broadcast & Communications Vehicles
Leadership Position in Broadcast & Communications Vehicles Worldwide Strong Customer Base Major Networks - ABC, CBS, FOX, NBC Cable Networks - CNN, Time Warner Satellite Uplink Service Market Relay House, PSSI, Calhoun, Arctek, Coastal, STS Export Market Canada, Morocco, Vietnam, Hong Kong Barriers
Slide 50: Broadcast & Communications Market Opportunity
Market Leader in Broadcast & Communications Market Opportunity Expand US Market Share Penetrate Asian Market Nextel FCC Frequency Reallocation Plan 2005 to 2007 New Products LT ENG Van COFDM Microwave
Slide 51: Homeland Security a HealthTronics
Homeland Security a Healthtronics
Slide 52: Homeland Security Market Breadth
Homeland Security Market Breadth: Mobile Communications Centers First Responder Units Mobile Emergency Ops Units Military Training Simulators Tactical transport Mobile Command Center Mobile Command Center
Slide 53: Homeland Security Federal Funding Programs
Homeland Security Federal Funding Programs $2.6B In Federal Funds are Allocated for 2005: Urban Area Security Initiative Grant Earmarked for Top 50 Metropolitan Areas State Homeland Security Grant States/Municipalities Response Capabilities 2005 Programs Initiated by DOHS Include: National Protectio
Slide 54: Homeland Security Strategic Relationships
Homeland Security Strategic Relationships Boeing Raytheon Titan Lockheed Martin Datapath Strong Customer Base FEMA FBI Florida Emergency Management Massachusetts State Police Federal Protection Service
Slide 55: Homeland Security Market Opportunities
Homeland Security Market Opportunities Strengthen our Position FEMA NASA Local/State Emergency Management Port Security Programs Development of Industry Alliances Joint Sales and Marketing Increased Market Presence Mobile Command Center Mobile Command Center
Slide 56: Conclusion
Conclusion Market Dominator Hi Barriers to Entry “Debt-Free” Segment Focused, Stand Alone Business Unit
Slide 57: 2005 Financial Forecast
2005 FINANCIAL FORECAST John Q. Barnidge Senior VP & CFO
Slide 58: Segment Summary
Segment Summary Income Statement 2005 Forecast ($ in millions) Urology Medical Devices Orthopaedics Specialty Vehicles Revenues $145 $27 $21 $110 EBITDA $85 $7 $5 $13 Adjusted EBITDA(1) $36 $7 $2 $13 (1) EBITDA less minority interest
Slide 59: Consolidated Summary Balance Sheet
Consolidated Summary Balance Sheet at 12/31/05 ($ in millions) 2005 Forecast Current Assets $134 Total Assets $507 Current Liabilities $71 Long-Term Debt $123 Stockholders’ Equity $241 Total Liabilities & Equity $507
Slide 60: Key Financial Statistics
Key Financial Statistics ($ in millions) 2005 Forecast (Projected 12/31/05) Total Debt $124 Cash (30) Net Debt $94 Ratios: Funded Debt to EBITDA 2.47x A/R Days Sales Outstanding 36.4 Interest Coverage (Adjusted EBITDA/Interest Expense) 6.05x Net Debt Leverage (Net Debt/LTM Adjusted EBITDA) 1.87x Net
Slide 61: 2005 Forecast Pro Forma Free-Cash Flow
2005 Forecast Pro Forma Free-Cash Flow Modified Cash Basis GAAP Adjusted EBITDA $50 $50 Interest Expense (8) (8) Income Tax Expense --- (11) Cap X, Net (6) (6) $36 $25 (1) Represents mid-point of estimates range.
Slide 62: Consolidated Summary Income Statement
Consolidated Summary Income Statement (1) ($ in millions) 2005 Forecast Revenues $303 Adjusted EBITDA $50 EPS Range $0.48—$0.53 (1) Represents mid-point of estimates range.
Slide 63: Q&A Session
ral Healthtronics Q&A SESSION The New HealthTronics
HealthTronics — Investor Presentation (December 2004) on 6ix